Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment

Nucleosides, Nucleotides and Nucleic Acids

Volumn 33, Issue 4-6, 2014, Pages 403-412

  Peters, Godefridus J ^a   Honeywell, Richard J ^a   Maulandi, Marie ^a,b   Giovannetti, Elisa ^a   Losekoot, Nienke ^a   Etienne Grimaldi, Marie Christine ^c   Milano, Gerard ^c   Serdjebi, Cindy ^b   Ciccolini, Joseph ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

cytarabine; Cytidine deaminase; gemcitabine; protein assays

Indexed keywords

CYTARABINE; CYTIDINE DEAMINASE; GEMCITABINE; DEOXYCYTIDINE;

ADULT; ARTICLE; BICINCHONINIC ACID ASSAY; BLOOD; BLOOD COMPARTMENT; BLOOD SAMPLING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ENZYME ACTIVITY; ENZYME ASSAY; ERYTHROCYTE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; PLASMA; REPRODUCIBILITY; SERUM; SEX DIFFERENCE; SPECTROPHOTOMETRY; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; ECONOMICS; METABOLISM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; COST-BENEFIT ANALYSIS; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; ENZYME ASSAYS; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84903177400     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2014.894196     Document Type: Article

References (24)

1. Peters, G.J.; Veerkamp, J.H. Purine and pyrimidine metabolism in peripheral blood lymphocytes. Int. J. Biochem. 1983, 15, 115-123.
2. Moyer, J.D.; Oliver, J.T.; Handschumacher, R.E. Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res. 1981, 41, 3010-3017.
3. Peters, G.J.; Veerkamp, J.H. Pyrimidine metabolism in rat brain cortex and liver. Adv. Exp. Med. Biol. 1984, 165A, 531-534.
4. Giovannetti, E.; Tibaldi, C.; Falcone, A.; Danesi, R.; Peters, G.J. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. J. Clin. Oncol. 2010, 28, e221-e222.
5. Pels Rijcken, W.R.; Overdijk, B.; van den Eijnden, D.H.; Ferwerda, W. Pyrimidine nucleotide metabolism in rat hepatocytes: evidence for compartmentation of nucleotide pools. Biochem. J. 1993, 293 (Pt 1), 207-213.
6. Chalmers, I.M.; Thomson, G.T.; Desjardins, P. Serum cytidine deaminase as a laboratory test for acute inflammation in rheumatoid arthritis. Ann. Rheum. Dis. 1988, 47, 173-174.
7. Bergman, A.M.; Pinedo, H.M.; Peters, G.J. Determinants of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine). Drug Res. Updates 2002, 5, 19-33. (erratum: 5, 176).
8. Elnaggar, M.; Giovannetti, E.; Peters, G.J. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Current Pharm. Design 2012, 18, 1811-1829.
9. Yonemori, K.; Ueno, H.; Okusaka, T.; et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin.Cancer Res. 2005, 11, 2620-2624.
10. Mercier, C.; Raynal, C.; Dahan, L.; et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet. Genomics 2007, 17, 841-844.
11. Bengala, C.; Guarneri, V.; Giovannetti, E.; et al. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br. J. Cancer 2005, 93, 35-40.
12. Tibaldi, C.; Giovannetti, E.; Tiseo, M.; Leon, L.G.; DIncecco, A.; Loosekoot, N.; Bartolotti, M.; Honeywell, R.J.; Cappuzzo, F.; Ardizzoni, A.; Peters, G.J. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine/platinum-treated advanced non-small-cell lung cancer patients. Ann. Oncol. 2012, 23, 670-677.
13. Tibaldi, C.; Giovannetti, E.; Vasile, E.; Mey, V.; Laan, A.C.; Nannizzi, S.; Di Marsico, R.; Antonuzzo, A.; Orlandini, C.; Ricciardi, S.; Del Tacca, M.; Peters, G.J.; Falcone, A.; Danesi, R. Correlation of cytidine deaminase, ercc1 and xpd polymorphisms with response and survival in gemcitabine/cisplatin- treated advanced non-small-cell lung cancer patients. Clin. Cancer Res. 2008, 14, 1797-803.
14. Ciccolini, J.; Dahan, L.; Andre, N.; et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 2010, 28, 160-165.
15. Ciccolini, J.; Mercier, C.; Dahan, L.; Andre, N. Integrating pharmacogenetics into gemcitabine dosing-time for a change? Nat. Rev. Clin. Oncol. 2011, 8, 439-444.
16. Mercier, C.; Dupuis, C.; Blesius, A.; Fanciullino, R.; Yang, C.G.; Padovani, L.; Giacometti, S.; Frances, N.; Iliadis, A.; Duffaud, F.; Ciccolini, J. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother. Pharmacol. 2009, 63, 1177-1180.
17. Fukunaga, A.K.; Marsh, S.; Murry, D.J.; Hurley, T.D.; McLeod, H.L. Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics. J. 2004, 4, 307-314.
18. Gilbert, J.A.; Salavaggione, O.E.; Ji, Y.; Pelleymounter, L.L.; Eckloff, B.W.; Wieben, E.D.; Ames, M.M.; Weinshilboum, R.M. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 2006, 12, 1794-1803.
19. Sugiyama, E.; Kaniwa, N.; Kim, S.R.; et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 2007, 25, 32-42.
20. Giovannetti, E.; Laan, A.C.; Vasile, E.; Tibaldi, C.; Nannizzi, S.; Ricciardi, S.; Falcone, A.; Danesi, R.; Peters, G.J. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleos. Nucleot. Nucl. 2008, 27, 720-725.
21. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
22. Stoscheck, C.M. Increased uniformity in the response of the coomassie blue G protein assay to different proteins. Anal. Biochem. 1990, 184, 111-116.
23. Mahfouz, R.Z.; Jankowska, A.; Ebrahem, Q.; Gu, X.; Visconte, V.; Tabarroki, A.; et al. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin. Cancer Res. 2013, 19, 938-948.
24. Ciccolini, J.; Peters, G.J.; Giovannetti, E. Gender, cytidine deaminase, and 5-aza/decitabine. Clin. Cancer Res. 2013, 19, 3105.